Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. news centers on the company's completed plan of arrangement, under which XenoTherapeutics acquired all issued and outstanding common shares, and the related removal of ESSA common stock from Nasdaq listing and Section 12(b) registration. Recurring updates also address shareholder voting matters, material agreements, common-share, option and warrant disclosures, governance, risk factors, clinical or regulatory disclosures, and operating and financial results.
ESSA Pharma Inc. (Nasdaq: EPIX) announced the first patient has been dosed in a Phase 1 clinical trial for EPI-7386, targeting metastatic castration-resistant prostate cancer (mCRPC) patients who have failed standard treatments. This small molecule inhibitor aims to demonstrate safety and tolerability while exploring its pharmacokinetic and anti-tumor effects. Approximately 18 patients will participate in the dose escalation phase, with further expansion expected. CEO David Parkinson highlighted this milestone as a step towards offering new treatment options for mCRPC patients.
ESSA Pharma Inc. (Nasdaq: EPIX) presented promising preclinical data on its drug candidate EPI-7386 at the 2020 AACR Virtual Annual Meeting II. The data confirm full-length androgen receptor (AR) engagement and demonstrate EPI-7386's ability to inhibit AR activity effectively, showing superior results over enzalutamide in certain models. Toxicology studies indicate a favorable safety profile, with the starting clinical dose set at 200 mg daily. ESSA plans to initiate a Phase 1 study targeting patients with castration-resistant prostate cancer, addressing a critical unmet need in cancer treatment.